April 12, 2012 - Abiomed Inc., a provider of heart support technologies, announced it has received CE marking approval in the European Union to market the Impella cVAD device, a new percutaneous Impella heart pump that provides peak flow of approximately 4 liters of blood per minute. The Impella cVAD is designed to provide temporary circulatory support via a minimally invasive, catheter-based pump that is insertedpercutaneously, without the need for surgical intervention.
The Impella cVAD further enhances Abiomed’s product portfolio, providing physicians with the clinical flexibility to offer increased flow for patients requiring more hemodynamic support. The increased flow is delivered on the same console platform, 9 French catheter, and introducer as the Impella 2.5.
“We are proud to announce the commercial European availability of the new Impella cVAD device and the growing Abiomed product portfolio,” said Michael R. Minogue, chairman, president and CEO, Abiomed.
Full commercial availability of the Impella cVAD in the European market is expected by summer 2012.
According to the labeling under CE mark in Europe and other countries, the Impella cVAD (intracardiac pump for supporting the left ventricle) is intended for clinical use in cardiology and cardiac surgery for up to five days for the following indications, as well as others: the Impella cVAD is a circulatory support system for patients with reduced left ventricular function, e.g., post-cardiotomy, low output syndrome, cardiogenic shock after acute myocardial infarction, or for myocardial protection after acute myocardial infarction; the Impella cVAD may also be used as a cardiovascular support system during coronary bypass surgery on the beating heart, particularly in patients with limited preoperative ejection fraction with a high risk of postoperative low output syndrome; support during high-risk percutaneous coronary intervention (PCI); post PCI.
The Impella cVAD is not currently cleared for sale or use in the United States.
For more information: www.abiomed.com
June 19, 2024 
